Human Prealbumin (Transthyretin, TTR) AssayMax™ELISA KitHuman Prealbumin (Transthyretin, TTR) AssayMax™ELISA Kit
Move your mouse over image or click to enlarge

Human Prealbumin (Transthyretin, TTR) AssayMax™ELISA Kit

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.

Cat# Size Price Qty Buy
EP3010-1 96 Well Plate £260.00

Additional Information

Property Value or Rating
Manufacturer Assaypro, LLC.
Product Type AssayMax™ ELISA Kits
Samples Serum, Urine, Saliva, Milk, Cell Culture, CSF
Species Human
Reactivity Human
Assay Format Sandwich ELISA
Product Size 96 Well Plate
Range 0.122-31.25 ng/ml
Plex Number 1
Storage Refer to component labels for details
Entrez Gene 7276
Omim 176300
UniProt P02766
UniGene Hs.427202
Special Notes For Research Use Only, Not To Be Used For Diagnostic Purposes
References * Escher N et al. (2007) Posttranslational Modifications of Transthyretin Are Serum Markers in Patients with Mycosis Fungoides1. Neoplasia. 9(3): 254-259 
* Maheshwari A et al. (2009) Developmental changes in circulating IL-8/CXCL8 isoforms in neonates. Cytokine. 46(1):12-16 
* Wang FE et al (2010) MicroRNA-204/211 alters epithelial physiology. FASEB J. 24(5):1552-1571 
* Alvarez R et al. (2011) Sirna therapy for transthyretin (ttr) related ocular amyloidosis. Patent application: CA 2792291 A1 
* Mastricci AL et al. (2011) Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11 
* Perrin RJ et al. (2011) Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PloSOne Jan 12; 6(1):e16032 
* Sah D (2011) Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR). WIPO Patent Application US2010/055311 
* Wang F and Miller S (2011) Mir 204, mir 211, their anti-mirs, and therapeutic uses of same. USPTO Patent Applicaton 20110190378
* Alvarez R et al. (2012) Compositions and methods for inhibiting expression of transthyretin. Patent number: US8168775 B2 
* Velayudhan L et al. (2012) Plasma Transthyretin as a Candidate Marker for Alzheimer 
* Tsui H (2014) Neuropsychological and plasma biomarkers for detecting Alzheimer's disease. Brain Health Research Center. 
* Zhu L et al. (2014) Transthyretin as a novel candidate biomarker for preeclampsia. Exp Ther Med.7(5):1332-1336. Epub 2014 Feb 18 
* Pasella S (2015) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 2015 May 21 
* Kallanthottathil R et al. (2016) RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES. Patent: US9399775 B2, PCT/US2012/065691. 
* Pasella S et al. (2016) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 28(1):77-82 
* Ando Y et al. (2017) siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis. United States patent application: 20170096663 A1 

" title="

* Escher N et al. (2007) Posttranslational Modifications of Transthyretin Are Serum Markers in Patients with Mycosis Fungoides1. Neoplasia. 9(3): 254-259 
* Maheshwari A et al. (2009) Developmental changes in circulating IL-8/CXCL8 isoforms in neonates. Cytokine. 46(1):12-16 
* Wang FE et al (2010) MicroRNA-204/211 alters epithelial physiology. FASEB J. 24(5):1552-1571 
* Alvarez R et al. (2011) Sirna therapy for transthyretin (ttr) related ocular amyloidosis. Patent application: CA 2792291 A1 
* Mastricci AL et al. (2011) Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11 
* Perrin RJ et al. (2011) Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PloSOne Jan 12; 6(1):e16032 
* Sah D (2011) Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR). WIPO Patent Application US2010/055311 
* Wang F and Miller S (2011) Mir 204, mir 211, their anti-mirs, and therapeutic uses of same. USPTO Patent Applicaton 20110190378
* Alvarez R et al. (2012) Compositions and methods for inhibiting expression of transthyretin. Patent number: US8168775 B2 
* Velayudhan L et al. (2012) Plasma Transthyretin as a Candidate Marker for Alzheimer 
* Tsui H (2014) Neuropsychological and plasma biomarkers for detecting Alzheimer's disease. Brain Health Research Center. 
* Zhu L et al. (2014) Transthyretin as a novel candidate biomarker for preeclampsia. Exp Ther Med.7(5):1332-1336. Epub 2014 Feb 18 
* Pasella S (2015) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 2015 May 21 
* Kallanthottathil R et al. (2016) RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES. Patent: US9399775 B2, PCT/US2012/065691. 
* Pasella S et al. (2016) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 28(1):77-82 
* Ando Y et al. (2017) siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis. United States patent application: 20170096663 A1 

" target="_blank">

* Escher N et al. (2007) Posttranslational Modifications of Transthyretin Are Serum Markers in Patients with Mycosis Fungoides1. Neoplasia. 9(3): 254-259 
* Maheshwari A et al. (2009) Developmental changes in circulating IL-8/CXCL8 isoforms in neonates. Cytokine. 46(1):12-16 
* Wang FE et al (2010) MicroRNA-204/211 alters epithelial physiology. FASEB J. 24(5):1552-1571 
* Alvarez R et al. (2011) Sirna therapy for transthyretin (ttr) related ocular amyloidosis. Patent application: CA 2792291 A1 
* Mastricci AL et al. (2011) Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11 
* Perrin RJ et al. (2011) Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PloSOne Jan 12; 6(1):e16032 
* Sah D (2011) Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR). WIPO Patent Application US2010/055311 
* Wang F and Miller S (2011) Mir 204, mir 211, their anti-mirs, and therapeutic uses of same. USPTO Patent Applicaton 20110190378
* Alvarez R et al. (2012) Compositions and methods for inhibiting expression of transthyretin. Patent number: US8168775 B2 
* Velayudhan L et al. (2012) Plasma Transthyretin as a Candidate Marker for Alzheimer 
* Tsui H (2014) Neuropsychological and plasma biomarkers for detecting Alzheimer's disease. Brain Health Research Center. 
* Zhu L et al. (2014) Transthyretin as a novel candidate biomarker for preeclampsia. Exp Ther Med.7(5):1332-1336. Epub 2014 Feb 18 
* Pasella S (2015) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 2015 May 21 
* Kallanthottathil R et al. (2016) RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES. Patent: US9399775 B2, PCT/US2012/065691. 
* Pasella S et al. (2016) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 28(1):77-82 
* Ando Y et al. (2017) siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis. United States patent application: 20170096663 A1 

Related Documents